Kornimate/medical-research-clean huggingface dataset:
effectivness and safety of acupuncture combined with moxibustion for allergic rhinitis

Conditions: Rhinitis, Allergic, Perennial

Summary: a multi-centre clinical trial done by us（isrcen90807007）showed that active acupuncture had significantly greater effect on symptoms of allergic rhinitis than either sham acupuncture or no active treatment. the object of that study was to evaluate the effectiveness and safety of acupuncture for allergic rhinitis. as an explanatory research, acupuncture was defined as the only intervention for treatment group and sham acupuncture, no active treatment as its control groups. besides, acupuncture combined moxibustion showed better and longer effect than acupuncture on allergic rhinitis patients in our previous pilot study. according to this result, we are taking a pragmatic randomized controlled trial to further evaluate whether acupuncture combined moxibustion is more effective than conventional treatment.


Eligibility criteria:
inclusion criteria: each participant must have a diagnosis of ar by an otolaryngology doctor, according to the criteria listed in "allergic rhinitis and its impact on asthma" (aria 2008) symptoms that had persisted for more than 4 days per week for more than four consecutive weeks. at least one of the following rhinitis-associated conditions: nasal obstruction, rhinorrhea, sneezing and nasal itching. at least one positive result on an allergy skin prick reaction test at screening. - exclusion criteria: active tuberculosis autoimmune disorders severe chronic inflammatory diseases history of anaphylactic reactions specific immunotherapy \>3 years simultaneous participation in other clinical trials serious acute or chronic organic disease or mental disorder congenital nasal abnormalities pregnancy or breast feeding blood coagulation disorder and/or current use of anticoagulants allergy desensitisation therapy (current, during the past two years, or planned in the next two years) previous systemically administered corticosteroids, antihistamines, or decongestants in the last 1 months prior to enrollment -

Keywords: allergic rhinitis acupuncture moxibustion efficacy safety
evaluation of zapperclick device for relief from mosquito bites

Conditions: Insect Bites; Stings

Summary: mosquito bites commonly result in redness, swelling and itching. this study will determine if a device that emits a small piezo-electrical impulse can provide relief from these symptoms. volunteers entering the study will have a mosquito bite on one forearm. redness and irritation will be recorded periodically for 24 hours. comparing data from subjects randomised to the treatment or a placebo device will be analysed to determine effectiveness of the product. we will also ask the subjects their view on how easy the product is to use and clarity of instructions provided.


Eligibility criteria:
inclusion criteria: * known rection to mosquito bites * willing to attend clinic for 2 hours during measurements * informed written consent exclusion criteria: * hypersensitivity to bites or stings * atopic allergy * pacemaker * pregnant / breast feeding * use of other medication including pain killers
diet and muscle function in older adults

Conditions: Sarcopenia

Summary: this research study was conducted to investigate the effects of a high protein diet on the efficiency of energy use at rest and at low-levels of physical activity. the hypothesis was that a high intake of dietary protein would result in a less efficient use of energy in skeletal muscle in older adults.

this research study was conducted to investigate the effects of a high protein diet on the efficiency of energy use at rest and at low-levels of physical activity. the hypothesis was that a high intake of dietary protein would result in a less efficient use of energy in skeletal muscle in older adult

Eligibility criteria:
inclusion criteria: * 65 years and older exclusion criteria: * diabetic * acute symptoms of cardiovascular disease or congestive heart failure * uncontrolled hypertension * supplemental oxygen consumption at rest or during exercise * lactose intolerance * inability to ride a stationary cycle
brain dopamine function in adults with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of the study is to investigate the functional state of dopamine cells and the dopamine transporter in adhd subjects and controls to assess the effects of chronic methylphenidate treatment on dopamine cell function and dopamine transporter levels in adhd subjects.


Eligibility criteria:
inclusion criteria: * must give informed consent * must be between the ages of 18 and 45 years old. * must have a confirmed diagnosis of adhd * must have scored on a rating scale that indicate a significant level of symptom severity. * must have a childhood history of adhd must be documented using established test criteria. * must have had no previous medication treatment for adhd except for a short term treatment period of less than three months, which should have occurred at least six months prior to the study. * must have an interest in receiving long-term medication treatment for adhd. exclusion criteria: * must not test positive for psychoactive drugs during a urine drug screen. * must not be pregnant. * must not be breastfeeding. * must have no past or present history of dependence on alcohol or other drugs of abuse except nicotine or caffeine. * must have no past or present history of a psychiatric disorder except adhd. * must have no medical illness that may affect brain function. * must not have taken medication that may affect brain function. * must not have had head trauma with loss of consciousness (\> 30 minutes). * must not have significant anxiety or depression as determined by an established test. * must have no history of a significant learning disability. * must have no history of cardiovascular or endocrinological disease. * must have no history of coagulation disorder. * must have no history of sensitivity to lidocaine and/or prilocaine. * must have no history of claustrophobia. * contraindication to mri environment (presence of any implanted metallic objects such as cardiac/neural pacemakers, defibrillators, aneurysm clips, certain heart valves, spinal nerve stimulators, artificial joints/limbs, shrapnel/bullets, metal fragments in their eyes, cochlear implants, hearing aids, dental implants). * must have no history of glaucoma.

Keywords: brookhaven adhd dopamine methylphenidate pet
a study of ocrelizumab in participants with relapsing remitting multiple sclerosis (rrms) who have had a suboptimal response to an adequate course of disease-modifying treatment (dmt)

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with relapsing remitting multiple sclerosis (rrms) who have had a suboptimal response to an adequate course of a disease-modifying treatment (dmt). the study will consist of a screening period (up to 4 weeks), an open-label treatment period (96 weeks; with last dose administered at week 72), and a follow-up period of at least 2 years.


Eligibility criteria:
inclusion criteria: * have a definite diagnosis of rrms, confirmed as per the revised mcdonald 2010 criteria * have a length of disease duration, from first symptom, of less than (\<) 10 years * have received no more than two prior dmts, and the discontinuation of the most recent dmt was due to lack of efficacy * suboptimal disease control while on a dmt * expanded disability status scale (edss) of 0.0 to 4.0, inclusive, at screening * for women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug exclusion criteria: * secondary progressive multiple sclerosis (spms) or history of primary progressive or progressive relapsing multiple sclerosis (ms) * inability to complete an magnetic resonance imaging (mri) procedure * known presence of other neurological disorders * any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study * history or currently active primary or secondary immunodeficiency * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies * history of opportunistic infections * history or known presence of recurrent or chronic infection * history of malignancy * congestive heart failure * known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds
ultrasonographic evaluation of abdominal muscle thickness symmetry and correlation with pulmonary function

Conditions: Muscle Physiology; Adolescent Idiopathic Scoliosis

Summary: we aimed in this study: 1. to compare the ultrasonographic measurements of the abdominal muscles thickness symmetry in patients with adolescent idiopathic scoliosis (ais) and adolescent healthy individuals 2. to investigate the effect of measured thickness and symmetry on pulmonary function test.

this cross-sectional,case-control clinical study included 40 patients diagnosed with ais and 40 age and gender -matched healthy individuals. ais group was evaluated for localization of curvature and degree of curvature. ultrasonographic measurements and were performed of bilaterally abdominal muscle thickness in both groups. spirometry evaluation was performed in both groups. intragroup and intergroup data were compared.

Eligibility criteria:
inclusion criteria: * cobb angle over 10 degrees in radiological evaluation * between the ages of 10-18 and diagnosed with ais by a specialist physiatrist exclusion criteria: * history of previous spinal surgery * patients using brace * those with any diagnosis of scoliosis other than ais * those with a history of neuromuscular disease * previous spinal surgery * patients with neurological deficits on examination * patients with acute or chronic lung pathology * patients with abdominal surgery or injury * double curve or multiple curve * patients with concomitant chronic diseases * the child's legal guardian does not allow it to take the tests the control group: * 10-18 volunteer adolescents without any health problems, * in clinical evaluation: healthy adolescents (without any asymmetric findings on three-way inspection, adam's forward bend test and scoliometer) were included.

Keywords: abdominal muscle cobb angle imbalance spirometry ultrasonography
dbgap protocol: the pediatric cardiac genetics consortium (pcgc)

Conditions: Congenital Heart Disease

Summary: background: researchers do not know much about the causes of congenital heart disease (chd). they do know that many factors play a role. some factors are environmental. some are genetic. but few specific factors have been identified. and researchers do not know how many involve genes. they want to study data that has already been collected from people with chd and their families. objectives: to identify genetic variations related to chd. to study molecules related to vascular disease in order to learn new ways to treat it. eligibility: people who already participated in the pediatric cardiac genomics consortium (pcgc) study design: researchers will study data that was already collected in the pcgc. there will be no active participants. researchers will get access to the data through the coordinating center. they will not download data to local storage devices. the data will have no personally identifying information....

current understanding of the causes of congenital heart disease (chd) is limited, but chd is known to be multifactorial and affected by a combination of environmental, teratogenic, and genetic causes. furthermore, both genetic and environmental factors have been proposed to act as disease modifiers, accounting for a wide variation in phenotypic expression and clinical outcomes of these disorders. to date however, few specific genetic or environmental causative factors have been identified, nor is it even known what proportion of cases involve genetic factors.

Eligibility criteria:
* retrospective analysis study. data will be analyzed from subjects from cardiovascular disease databases.

Keywords: dbgap
effects of aquatic physical training program on cardiorespiratory variables in patients with copd

Conditions: Adverse Effects in the Aquatic Exercises

Summary: we have as hypothesis that the aquatic aerobic physical training program can help promote beneficial adaptations on the cardiovascular, respiratory and systemic inflammation variables, functional capacity and quality of life in patients with chronic obstructive pulmonary disease (pulmonary emphysema).

first paragraph * aquatic aerobic physical training program * beneficial adaptations next paragraph * cardiovascular * respiratory * systemic inflammation * functional capacity * quality of life

Eligibility criteria:
inclusion criteria: * diagnosis of copd ( gold i / ii / iii / iv rating ) * clinically stable * low level of physical activity , according to the ipaq ( international physical activity questionnaire ) * absence of exacerbation in the last three months * do not participate in a regular exercise program in the past six months exclusion criteria: * diabetes mellitus * endocrine disorders * chronic renal failure * liver diseases * other lung diseases or inflammatory diseases associated * cardiac * use of drugs that prevented physical performance * musculoskeletal and neuromuscular changes that make it impossible to run experimental protocols * dermatological disorders ( cutaneous fistulas , infected wounds , ringworm skin , varicose ulcers ) * hypersensitivity to the product used for the treatment of pool water * rabies

Keywords: pulmonary disease, chronic obstructive
sedation and analgesia for transjugular liver biopsy: a randomized double blind placebo controlled trial

Conditions: Cirrhosis; Chronic Hepatitis; Anxiety

Summary: transjugular liver catheterisation allows the measurement of hepatic venous pressure gradient (hvpg) and the sampling of liver tissue but patient's tolerance to the procedure is unknown. the aim of this study was to assess tolerance to transjugular hepatic liver biopsy with or without conscious sedation/analgesia.

consecutive patients undergoing transjugular liver biopsy will be randomly assigned to receive either placebo or midazolam (0.02 mg/kg) or 0.02 mg/kg midazolam combined with 1 mg/kg pethidine before the procedure.

Eligibility criteria:
inclusion criteria: * suspected liver disease * known liver disease exclusion criteria: * liver transplants * hepatocellular carcinoma * hypersensitivity or allergy to benzodiazepines or morphinic derivatives

Keywords: liver biopsy
galnt4 in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the expression of galnt4 in blood with acute coronary syndrome

emerging evidences have linked galnts to cardiovascular disease or susceptibility to cad.galnt4, a member of the galnac-ts family,contributes to the initiation of o-linked. polymorphisms in galnt4 have been linked with incidence of mi in an irish population, probably that o-glycosylation of psgl-1 by galnac-t4 may be important for many p-selectin mediated inflammation.however, there is few relevant studies about the expression of galnt4 in patients with acute coronary syndrome.this study valuates the expression of galnt4 in patients with acute coronary syndrome.

Eligibility criteria:
inclusion criteria: * diagnosed as acute coronary syndrome,including stemi,nste-acs,or diagnosed as sap by cag. * with left ventricular ejection fraction（lvef）\>=45% * written informed consents are obtained * admitted within 24 hours after chest pain attacked(except sap) exclusion criteria: * • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy * complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction * with acute or chronic infection, surgery or trauma in the last month * secondary hypertension, severe liver dysfunction,severe renal insufficiency * with abnormal thyroid function or allergy to iodine agent * refusal to sign the informed consent

Keywords: galnt4
a study of all-cause and cardiovascular mortality in type 2 diabetes patients using basal insulin detemir and glargine

Conditions: Diabetes Mellitus, Type 2

Summary: this study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in united kingdom (uk). the data for this study will be drawn from the clinical practice research datalink (cprd) register.


Eligibility criteria:
inclusion criteria: * diagnosis (ever) of type 2 diabetes * prescription (ever) of basal insulins glargine or detemir * insulin-naïve until initiation of basal insulins glargine or detemir * aged 40 years or older at start of observation period exclusion criteria: * diagnosis of type 1 diabetes
reflux esophagitis phase iii study (maintenance treatment)

Conditions: Reflux Esophagitis

Summary: the primary objective of this study is to evaluate the efficacy of esomeprazole 20 mg once daily for 24 weeks on maintenance of reflux esophagitis in patients with healed reflux esophagitis in comparison with omeprazole 10 mg once daily and esomeprazole 10 mg once daily by assessment of presence/absence of recurrence of reflux esophagitis throughout the treatment period (from the randomisation to the treatment completion) according to the los angeles classification.


Eligibility criteria:
inclusion criteria: * patients with healed reflux esophagitis verified by egd in the preceding study (d961hc00002) * patients with endoscopically verified healed reflux esophagitis by egd receiving general treatment with ppi exclusion criteria: * gastric or duodenal ulcer verified by egd within 12 weeks before randomisation. * use of any ppi from 14 days before egd performed at the screening visit to the day of randomisation.

Keywords: reflux esophagitis
role of uterine manipulator in hysterectomy - ro.man.hy

Conditions: Endometrial Cancer

Summary: prospective multicentric randomized trial to evaluate the role of uterine manipulator on laparoscopic/robotic total hysterectomy for the treatment of early stage g1 - g2 endometrial cancer (international federation of gynecology and obstetrics - figo stages ia-ib).

this multicentric prospective randomized phase iii trial is aimed to verify if the use of uterine manipulator for laparoscopic/robotic treatment of early stage endometrial cancer can influence the impact of peritoneal cytology and lymph vascular space invasion (lvsi) and the outcomes in terms of perioperative and oncological (disease free survival - dfs, overall survival - os) outcomes.

Eligibility criteria:
inclusion criteria: for patients * age \> 18 \< 80 years * patient's informed consent * american society of anesthesiologists: \< class iii or iv * no actual pregnancies * body mass index (bmi) ≤ 35 for diseases * early stage endometrial cancer (ia-ib) * endometrioid histotype (g1-g2) exclusion criteria: for patients * age \> 18 \< 80 * actual pregnancies * previous gynecological cancer for disease * type ii endometrial cancer histotype * grade 3 endometrial cancer * advanced stage endometrial cancer (ii - iv) * previous radiotherapy on the pelvic field * uterine size larger than conform 12 weeks gestation or 9 cm in horizontal * necessity of laparotomic procedures

Keywords: uterin manipulator endometrial cancer laparoscopy robotic
acute haemodynamic impact of an iv glucose-injection

Conditions: Peritoneal Dialysis

Summary: patients with peritoneal dialysis will be administered an iv glucose-injection to evaluate the haemodynamic impact of this injection. the patients will be matched with healthy volunteers.


Eligibility criteria:
inclusion criteria: * \> 18 years old * stable clinical condition * either peritoneal dialysis (at least one month) either matched healthy subject exclusion criteria: * heart failure * diabetes requiring insulin treatment
radicle gi health: a study of health and wellness products on gi health and other health outcomes

Conditions: Digestion; Abdominal Pain; GI Disorders

Summary: a randomized, blinded, placebo-controlled study assessing the impact of health and wellness products on gastrointestinal (gi) health and other health outcomes

this is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the united states. eligible participants will (1) endorse a desire for less bloating or indigestion, (2) indicate an interest in taking a health and wellness product to potentially help their bloating or indigestion, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. those taking certain medications will be excluded. self-reported data are collected electronically from eligible participants over 7 weeks. participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. all study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Eligibility criteria:
inclusion criteria: * adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, and gender identities * resides in the united states * endorses less bloating or indigestion as a primary desire * has the opportunity for at least 20% improvement in their primary health outcome score * expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study exclusion criteria: * reports being pregnant, trying to become pregnant, or breastfeeding * unable to provide a valid us shipping address and mobile phone number * the calculated validated health survey (pro) score during enrollment represents less than mild severity * reports a diagnosis of liver or kidney disease * reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * unable to read and understand english * reports current enrollment in another clinical trial * lack of reliable daily access to the internet * reports current or recent (within 3 months) use of chemotherapy or immunotherapy * reports taking medications with a known moderate or severe interaction with any of the active ingredients studied, or a substantial safety risk: anticoagulants, antihypertensives, anti-anxiolytics, antidepressants, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, maois (monoamine oxidase inhibitors), or thyroid products * reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: nyhaa (new york heart association) class iii or iv congestive heart failure, atrial fibrillation, uncontrolled arrhythmias